CorMedix announced that for 2026, it expects revenue between $300 million and $320 million, compared to $310 million it reported in the full year 2025, according to preliminary data.
CorMedix (CRMD) exemplifies a high-growth stock with explosive sales, strong earnings momentum, and robust profitability, fitting a proven investment framework.
CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.
CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.
The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.
CorMedix Inc. fits a proven growth investing strategy with explosive revenue growth, soaring profits, and strong analyst revisions, signaling high potential.
CorMedix Inc (CRMD) identified as a top growth stock using Louis Navellier's strategy, showing explosive revenue growth, soaring earnings estimates, and strong profitability.
CorMedix (CRMD) excels in Louis Navellier's growth strategy with massive revenue growth, soaring earnings, and high ROE, making it a top stock to watch.
